Prevention of Hemolytic Disease of the Newborn (Erythroblastosis Fetalis)

Key points
- The antibody anti-Rho(D) is responsible for most severe instances of hemolytic disease of the newborn (erythroblastosis fetalis).
- Passive immunization against hemolytic disease of the newborn is achieved with Rho(D) immune globulin, a purified concentrate of antibodies against Rho(D) antigen.
- Hemolytic disease of varying degrees, from mild to serious, continues to occur in association with Rh subgroups (C, c, or E) or Kell, Kidd, and other factors.
- Moise KJ Jr: Management of rhesus alloimmunization in pregnancy.
The antibody anti-Rho(D) is responsible for most severe instances of hemolytic disease of the newborn (erythroblastosis fetalis). About 15% of whites and much lower proportions of blacks and Asians are Rho(D)-negative. If an Rho(D)-negative woman carries an Rho(D)-positive fetus, she may develop antibodies against Rho(D) when fetal red cells enter her circulation during small fetomaternal bleeding episodes in the early third trimester or during delivery, abortion, ectopic pregnancy, abruptio placentae, or other antepartum bleeding problems. This antibody, once produced, remains in the woman's circulation and poses the threat of hemolytic disease for subsequent Rh-positive fetuses.
Passive immunization against hemolytic disease of the newborn is achieved with Rho(D) immune globulin, a purified concentrate of antibodies against Rho(D) antigen. The Rho(D) immune globulin (one vial of 300 ug intramuscularly) is given to the mother within 72 hours after delivery (or spontaneous or induced abortion or ectopic pregnancy). The antibodies in the immune globulin destroy fetal Rh-positive cells so that the mother will not produce anti-Rho(D). During her next Rh-positive gestation, erythroblastosis will be prevented. An additional safety measure is the administration of the immune globulin at the 28th week of pregnancy. The passive antibody titer that results is too low to significantly affect an Rh-positive fetus. The maternal clearance of the globulin is slow enough that protection will continue for 12 weeks.
Hemolytic disease of varying degrees, from mild to serious, continues to occur in association with Rh subgroups (C, c, or E) or Kell, Kidd, and other factors. Therefore, the presence of atypical antibodies should be checked in the third trimester of all pregnancies.
Moise KJ Jr: Management of rhesus alloimmunization in pregnancy. Obstet Gynecol 2002;100:600.
Prevention of Rh D alloimmunization. Clinical management guidelines for obstetrician-gynecologists. ACOG Practice Bulletin No. 4, 1999. Int J Gynaecol Obstet 1999;66:63.
Written and revised by
David Cohen, M.D.
Our doctors write and review articles for accuracy and keep them up to date.
health.am provides general information, not medical advice. Always consult a qualified health professional about your own health.
Explore health topics
More in this topic
Women's Health →
NewsEarly menopause raises heart disease risk
Women who go through menopause early, before age 46, may have more than twice the risk of having a heart attack, stroke or other cardiovascular event later in life, researchers reported on Monday. The risk was the same…
23 June 2010
NewsUS: Screen babies for 'bubble boy disease'
"Bubble boy disease" is now part of national U.S. newborn screening guidelines, adopted by Secretary of Health and Human Services Kathleen Sebelius last week. The disease - formally known as severe combined…
29 May 2010
NewsAntidepressant tied to risk of newborn heart defect
Women who use the antidepressant bupropion during early pregnancy may have an increased risk of having a baby with a particular type of heart defect, a new study suggests. Researchers caution that it is not clear…
5 May 2010






